Human study maps mitragynine and 7-OH exposure after kratom extract doses

Why it matters

The study supplies human pharmacokinetic measurements for a concentrated extract, which can help clinicians and researchers understand that extract formulations differ from leaf powder or tea. It does not establish clinical safety or benefit.

The big picture

Kratom products vary considerably in alkaloid content and formulation. The authors noted that data for concentrated extracts had been lacking; they also disclosed that all authors consulted for the product sponsor.

Key findings

• The study tested extract doses containing 9.9, 29.6, or 59.2 mg of mitragynine after single and 15 daily doses.
• Mitragynine and 7-hydroxymitragynine peak concentrations increased with dose after both dosing schedules.
• Median time to peak concentration was about 1.3 hours after single doses and 1.7 to 2.3 hours after multiple doses.
• Exposure measures increased with dose but were less than 1.4 times the amount predicted by strict dose proportionality.
• The authors reported that comparable-dose extract preparations may yield greater overall mitragynine exposure than dried leaf powder or tea.

What they say

The authors concluded that “concentrated kratom extracts may yield greater overall mitragynine exposure than dried kratom leaf powder or kratom tea preparations administered at comparable doses.”

Bottom line

Concentrated extract formulations produced dose-related human mitragynine and 7-OH exposure, underscoring why formulation matters when interpreting kratom research or safety reports.